Darzalex performs well in Janssen's rare disease study

New data from Janssen supports the use of Genmab-developed drug Darzalex Faspro to treat the rare disease AL amyloidosis.

Photo: Joost Melis / Genmab / PR

On Wednesday, Johnson & Johnson-company Janssen Pharmaceuticals, which produces and sells Genmab's blockbuster drug Darzalex, announced positive trial results for the subcutaneous (under the skin) version of this drug for treating the rare disease amyloid light-chain (AL) amyloidosis.

The results stem from the combination study Andromeda, which is also the basis of the positive opinion which the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) published on Friday last week.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs